Anthony G. Quinn, MBChB (M.D.), Ph.D., FRCP most recently served as Synageva's Executive Vice President, Head of Research & Development and Chief Medical Officer from August 2009 until its acquisition by Alexion Pharmaceuticals in 2015 for a total transaction value of $ 8.4 billion net of cash. During his tenure at Synageva, he led the company’s R&D and clinical programs and strategies and played a key role in securing the European and U.S. approvals of Kanuma™ for Lysosomal Acid Lipase Deficiency. Under his leadership, Synageva developed and progressed its rare disease drug pipeline which included the transition of SBC-103, an enzyme replacement therapy for MPS IIIB into clinical studies and the discovery of a novel inhibitor of tissue calcification. Prior to joining Synageva, he was Vice President and Global Head of Clinical Research & Exploratory Development for Inflammation at Roche. In this role, Dr. Quinn was responsible for leading both exploratory clinical development activities for rheumatology and respiratory indications and biomarker and translational medicine activities supporting the late stage clinical and registration phase for MabThera/Rituxan®, Actemra® and Ocrelizumab. Dr. Quinn joined Roche in 2005 and held positions of increasing responsibility in translational medicine and exploratory development across a broad range of therapeutic areas including CNS, virology and inflammation. Prior to joining Roche, he was Director of Experimental Medicine at AstraZeneca, Charnwood in the UK, and before that he was Professor of Dermatology at Barts & The London School of Medicine, London, England. He has authored or co-authored more than 50 peer-reviewed journal articles, book chapters, reviews and editorials, in a range of areas including rare diseases, Hedgehog signaling and the molecular biology of non-melanoma skin cancer. He received his Bachelor of Medical Science with First Class Honours and his M.B.Ch.B. (M.D.) with commendation from the University of Dundee, UK. Dr. Quinn trained in internal medicine, dermatology and molecular biology at the University of Newcastle upon Tyne and was also awarded his Ph.D. there. He completed a postdoctoral fellowship at University of California, San Francisco, and is a fellow of the Royal College of Physicians London.

 Internal medicine   dermatology   molecular biology